Profile of neratinib and its potential in the treatment of breast cancer by Feldinger, Katharina & Kong, Anthony
 
 
Profile of neratinib and its potential in the treatment
of breast cancer
Feldinger, Katharina; Kong, Anthony
DOI:
10.2147/BCTT.S54414
License:
Creative Commons: Attribution-NonCommercial (CC BY-NC)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Feldinger, K & Kong, A 2015, 'Profile of neratinib and its potential in the treatment of breast cancer', Breast
Cancer, vol. 2015, no. 7, pp. 147-162. https://doi.org/10.2147/BCTT.S54414
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 12/01/2016. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are
available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0)
License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further
permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work,
please see paragraphs 4.2 and 5 of our Terms.
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
© 2015 Feldinger and Kong. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to 
request permission may be found at: http://www.dovepress.com/permissions.php
Breast Cancer: Targets and Therapy 2015:7 147–162
Breast Cancer: Targets and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
147
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/BCTT.S54414
Profile of neratinib and its potential in the 
treatment of breast cancer
Katharina Feldinger1
Anthony Kong2
1Department of Oncology, The 
Weatherall Institute of Molecular 
Medicine, University of Oxford, 
Oxford, 2The Robert Aitkin Institute, 
School of Cancer Sciences, University 
of Birmingham, Birmingham, UK
Correspondence: Anthony Kong 
The Robert Aitkin Institute, School 
of Cancer Sciences, University of 
Birmingham, Birmingham B15 2TT, UK 
Tel +44 121 414 9294 
Fax +44 121 414 8046 
email a.h.kong@bham.ac.uk
Abstract: The HER (ErbB) receptor tyrosine kinase receptors are implicated in many cancers 
and several anti-HER treatments are now approved. In recent years, a new group of compounds 
that bind irreversibly to the adenosine triphosphate binding pocket of HER receptors have been 
developed. One of these compounds, neratinib, has passed preclinical phases and is currently 
undergoing various clinical trials. This manuscript reviews the preclinical as well as clinical data 
on neratinib. As a pan-HER inhibitor, this irreversible tyrosine kinase inhibitor binds and inhibits 
the tyrosine kinase activity of epidermal growth factor receptors, EGFR (or HER1), HER2 and 
HER4, which leads to reduced phosphorylation and activation of downstream signaling pathways. 
Neratinib has been shown to be effective against HER2-overexpressing or mutant tumors in vitro 
and in vivo. Neratinib is currently being investigated in various clinical trials in breast cancers and 
other solid tumors, including those with HER2 mutation. Earlier studies have already shown prom-
ising clinical activity for neratinib. However, more translational research is required to investigate 
biomarkers that could help to predict response and resistance for selection of appropriate patients 
for treatment with neratinib, either as monotherapy or in combination with other drug(s).
Keywords: neratinib, HKI 272, pan-HER inhibitor, irreversible tyrosine kinase inhibitor, HER 
(ErbB), breast cancer
Introduction
The family of HER (ErbB) receptor tyrosine kinases consists of four members, ie, 
epidermal growth factor receptors [EGFR (HER1 or ErbB1), HER2 (ErbB2, neu), 
HER3 (ErbB3), and HER4 (ErbB4)].1 Overexpression, mutation, or aberrant activity of 
these receptors has been implicated in various types of cancer. HER2 is overexpressed in 
approximately  15%–20% of all breast cancers1 and is correlated with poor prognosis.2 
HER receptors comprise an extracellular domain, a single transmembrane domain, and an 
intracellular tyrosine kinase domain.3 A disintegrin and metalloproteinases (ADAMs) shed 
the ligands that are needed for HER member activation. Eleven ligands are known to bind 
to the different receptors of the family, as shown in Figure 1;3 however, HER2 does not 
have a known ligand.4 Ligand binding induces a conformational change in HER receptors 
1, 3, and 4, which exposes the dimerization domain. This facilitates homodimerization 
or heterodimerization and transphosphorylation of the tyrosine kinase domains.5 Sub-
sequently, downstream signaling pathways, most prominently the phosphatidylinositide 
3-kinase and mitogen-activated protein kinase pathways, are activated and promote survival 
and proliferation.6–8 HER2 adopts a constant “open” conformation, with the dimerization 
domain being always available.9 It was shown to be the preferred dimerization partner 
within the HER receptor network and it can also form potent homodimers.10
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Development of neratinib to target HER 
family kinase activity
Neratinib (HKI-272, Puma Biotechnology Inc., Los Angeles, 
CA, USA) is an oral tyrosine kinase inhibitor (TKI). The 
scientific approach behind the development of this and other 
similar compounds was to design small molecules that could 
bind to the tyrosine kinase domain and inhibit its interaction 
with adenosine triphosphate (ATP) in order to prevent recep-
tor phosphorylation. A selection of compounds with relevant 
references is listed in Figure 2 and Table 1, although a direct 
comparison of IC
50
 values is difficult due to different assay 
conditions. Earlier compounds such as erlotinib (Tarceva®) 
and gefitinib (Iressa®), which are approved in non-small 
cell lung cancer (NSCLC), or lapatinib (Tyverb), which is 
licensed for HER2-positive breast cancer, were designed as 
reversible compounds that directly compete with ATP for 
binding. However, considering the high endogenous ATP 
levels within the cell (mM range) and that drug resistance 
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Figure 1 HER member family and activation. 
Abbreviations: ADAMs, A disintegrin and metalloproteinases; EGF, epidermal growth factor; TGF, tumor growth factor; AREG, amphiregulin; EPG, epigen; HB-EGF, 
heparin-binding EGF-like growth factor; BTC, betacellulin; EPR, epiregulin; NRG, neuregulin; PI3K, phosphatidylinositide 3-kinase; PTEN, phosphatase and tensin homolog; 
PKC, protein kinase C; STAT, signal transducer and activator of transcription; JAK, Janus kinase.
Figure 2 Chemical structure of tyrosine kinase inhibitors. 
Note: Adapted Data from PubChem.16–21
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Table 1 Comparison of various tyrosine kinase inhibitors
Compound Binding IC50 (nM)
EGFR HER2 HER4
Gefitinib Reversible 27–3312,* 
0.4–4.713,**
$3,70012,* 
416–1,83013,**
 
293–32313,**
Erlotinib Reversible 212,* 
0.9–1.713,**
.1,00012,* 
238–69813,**
 
579–75613,**
Lapatinib Reversible 1112,* 
0.3–17
912,* 
6–25
36712,* 
18–30
Neratinib Irreversible 9214,*** 5914,***
Afatinib Irreversible 0.2–0.713,** 7–2513,** 0.7–1.713,**
Canertinib Irreversible 0.812,* 
0.3–1.713,**
1912,* 
22–7213,**
712,* 
0.8–1013,**
Dacomitinib Irreversible 615,# 4615,# 7415,#
Notes: Measuring IC50 values is highly dependent on the assay set-up; please refer 
to individual references for more information on exact methods. *Purified enzyme 
kinases were used to calculate in vitro IC50 values (please refer to review); **purified 
cytoplasmic tyrosine kinase domains were used in in vitro kinase assays (non-
radioactive for EGFR and HER2 and radioactive for HER4); ***purified cytoplasmic 
domains were used to measure autophosphorylation using a time-resolved 
fluorometry assay; #purified catalytic domains were used in in vitro enzyme-linked 
immunosorbent-based kinase assays.
Abbreviations: EGFR, epidermal growth factor receptor; TKR, tyrosine kinase 
receptor.
is a common problem with these reversible inhibitors, there 
was a need to develop a more potent inhibitor that could have 
enhanced and sustained antitumor activity.11
A variety of irreversible inhibitors of quinazoline deriva-
tives has been developed, including dacomitinib and afatinib, 
which showed a high affinity and efficacy in inhibiting 
autophosphorylation of EGFR.22 Neratinib is a compound 
comprising a quinolone core with the same reactive substitu-
ent as afatinib, but with a lower affinity and biochemical 
potency.22 The effectiveness of these compounds is based 
on a Michael acceptor moiety, which is designed to form a 
covalent bond with the conserved cysteine residue at the lip 
of the EGFR ATP binding site.23–25 Neratinib interacts with 
cysteine residues Cys-773 and Cys-805 in EGFR and HER2, 
respectively, in the ATP binding pocket.11 Due to this selective 
binding, a higher specificity of the compound is achieved. It 
was shown that neratinib did not significantly inhibit serine-
threonine kinases such as AKT in cell-free assays. Tyrosine 
kinases tested included c-met, Kdr (vascular endothelial 
growth factor receptor 2), and Src, and either no effect or 
a 14-fold and 24-fold decreased efficacy, respectively, was 
found in comparison with HER2.14
Neratinib was developed as a modification of EKB-569 
(pelitinib), an irreversible EGFR inhibitor developed by 
Wyeth Pharmaceuticals.11 The chemical name is 2-buten-
amide, N-[4- [[3-chloro-4-(2-pyridinylmethoxy) phenyl] 
amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-, 
(2E)-, (2Z) -2-butenedioate (1:1). In comparison with EKB-
569, neratinib has a lipophilic 2-pyridinylmethyl moiety at 
the para-position of the aniline and a lipophilic chlorine atom 
at the meta-position, which is thought to improve its activity 
against HER2.14,24 However, as the cysteine residue required 
for binding is conserved in three of the HER receptors, ie, 
EGFR, HER2, and HER4, neratinib is a pan-HER inhibitor.11 
Neratinib inhibits EGFR and HER2 at IC
50
 values of 92 nM 
and 59 nM, respectively; specific IC
50
 data for HER4 has 
not been published.14 However, the compound is similar to 
afatinib, so activity against HER4 can be expected and has 
indeed been shown previously.26,27
Efficacy of neratinib in preclinical models
As neratinib binds irreversibly to the ATP binding pocket 
of HER member receptor tyrosine kinases, it was hypoth-
esized that after binding a prolonged bioavailability in the 
blood would not be needed. Therefore, the efficacy of the 
compound would only depend on receptor turnover.11 Acute 
treatment with low doses of neratinib led to a decrease of 
HER2 and EGFR phosphorylation in HER2-overexpressing 
BT474 and EGFR-amplified A431 cells, respectively, which 
persisted even after the removal of the drug. However, the 
time point chosen was only 5 hours.14 Neratinib was shown 
to decrease tumor growth in EGFR and HER2-expressing 
cell lines in vitro, which was correlated with a decrease in 
cyclin D1 and an increased level of p27, leading to G1-S cell 
cycle arrest and an increased sub-G1 population, indicating 
apoptosis.14
HER2-positive breast cancer
Despite reasonable IC
50
 values with regard to both EGFR 
and HER2, several studies have shown that neratinib is 
more effective in HER2-positive breast cancers relative to 
other breast cancer subtypes. In a study using a panel of cell 
lines, we showed that the response to neratinib was corre-
lated with baseline HER2 and phosphorylated HER2 levels, 
but not with EGFR levels in vitro.26 Interestingly, neratinib 
decreased the activation of phosphatidylinositide 3-kinase 
and mitogen-activated protein kinase downstream pathways, 
and the activity against AKT and ERK could be correlated 
with efficacy.14,26,28 Other biomarker candidates that have been 
investigated in vitro include upregulation of RB1CC1, HER3, 
FOXO3a, and NR3C1 as well as downregulation of CCND1 
mRNA, all of which have been correlated with response to 
neratinib.29 In vivo, neratinib was shown to be more effective 
in decreasing xenograft tumor growth of EGFR-amplified 
(A431) and HER2-overexpressing (BT474 and SKOV3) cell 
lines compared with low EGFR and HER2-expressing cell 
lines (MCF-7 and MX-1) in athymic (nude) mice.14 However, 
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the decrease in tumor growth in the EGFR-dependent tumor 
model was less than that seen in HER-2-dependent tumors 
at comparable doses.14
Dual targeting of HER2-positive breast 
cancers and overcoming treatment 
resistance
Considerable effort has been made to target HER2  signaling. 
The first treatment approved by the US Food and Drug 
Administration was the monoclonal antibody trastuzumab 
(Herceptin®), which targets domain IV of the extracellular 
domain of HER2.9 Trastuzumab was approved in 1998 and 
has been shown to be effective, particularly in combination 
with chemotherapeutic agents, in the treatment of various 
stages of HER2-positive breast cancer.30–33 However, de novo 
or acquired resistance to trastuzumab is frequent and is still 
a subject of extensive research.
Previous reports identified phosphatase and tensin 
homolog (PTEN) deficiency,34,35 phosphatidylinositide 
3-kinase (PI3K) mutation,36 loss of p27,37 and reduced bind-
ing of the antibody due to HER2 cleavage38 or allosteric hin-
drance39,40 as mechanisms involved in trastuzumab resistance. 
Interestingly, it was also reported that treatment with trastu-
zumab led to an increased activation of other receptor tyrosine 
kinases, including the insulin-like growth factor 1 receptor 
(IGFR1)38 and c-Met.41 In addition, we have previously 
shown that trastuzumab induced an increase of ADAM10 and 
ADAM17 expression, which enhanced the release of the HER 
ligands betacellulin and heregulin (neuregulin), resulting in 
activation of HER receptors as well as downstream signaling 
pathways during prolonged treatment with trastuzumab.42,43 
A  ligand-dependent mechanism has also been reported in 
vitro with regard to lapatinib resistance.44,45
As shown in Figure 3, neratinib targets tyrosine kinase 
activity at the intracellular domain of the HER receptors 
(EGFR, HER2, and HER4), whereas trastuzumab targets the 
extracellular domain of HER2. This difference in mechanism 
of action would explain the improved response when both 
drugs are combined, since trastuzumab can induce ligand-
dependent activation of HER receptors,42,43 whereas neratinib 
inhibits the phosphorylation and activity of HER receptors. 
Indeed, it has been shown that neratinib can overcome trastu-
zumab resistance in vitro.26 It was reported that neratinib was 
able to suppress ligand-stimulated HER2–HER3 dimers and 
could effectively disrupt preformed HER2–HER3 dimers in 
non-HER2-overexpressing MCF7 cells more effectively than 
lapatinib.46 Additionally, both TKIs decreased internalization 
of the HER2 receptor from the cell membrane, leading to 
increased trastuzumab-induced antibody-dependent cellular 
cytotoxicity.46 It has been shown that during trastuzumab treat-
ment and resistance, HER4 cleavage and its translocation to 
the nucleus was increased; and nuclear HER4 was associated 
with a poor prognosis.27 However, cotreatment with neratinib 
decreased trastuzumab-induced nuclear HER4 in vitro and in 
BT474 xenograft models.27 In the same in vivo model, it was 
shown that trastuzumab and neratinib treatment in combina-
tion was more effective than either treatment alone.26
Additionally, neratinib was also shown to enhance 
response when added to mammalian target of rapamycin/
phosphatidylinositide 3-kinase inhibitors47 and the PARP 
inhibitor olaparib.48 These results, as well as those of the 
study from Seyhan et al28 point to the potential added  benefit 
Intracellular
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TKIs target the intracellular kinase domain –eg, neratinib 
H
ER
4
H
ER3
H
ER
2
EG
FR
Extracellular
ADAMs
P
P
P P P
Figure 3 Sites of interaction of trastuzumab and neratinib with HER receptors.
Abbreviations: ADAMs, A disintegrin and metalloproteinases; TKIs, tyrosine kinase inhibitors; EGFR, epidermal growth factor receptor.
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of using neratinib as a combinational treatment option 
alongside other targeted treatments as well as conventional 
chemotherapeutics.
We have recently shown that neuregulin (NRG1) can 
counteract the response to lapatinib, which was improved by 
the combination of lapatinib with pertuzumab, an antibody 
binding to the HER2 dimerization domain.45 It would thus 
be interesting to test whether NRG1 mediates resistance to 
neratinib and whether pertuzumab could also enhance the 
response to neratinib. In addition, since the combination of 
trastuzumab with new agent(s), including a heat shock protein 
90 inhibitor,49 was shown to be additional or synergistic, it 
will be interesting to test the combination of neratinib with 
these new agents. However, more data will be needed to guide 
the sequence and/or combinations of different compounds, 
which could benefit patients.
Neratinib for CNS metastasis  
in HER2-positive breast cancer
A major problem in the treatment of patients with HER2-
positive breast cancer is the high incidence of central nervous 
system (CNS) metastases. Although clinical studies suggest 
that patients with CNS metastases who receive trastuzumab 
have an increased overall survival compared with patients who 
do not, it is well understood that penetration of trastuzumab 
across the blood–brain barrier is inefficient.50 Therefore, there 
is a growing interest in using TKIs to target CNS disease in 
patients with HER2-positive breast cancer. One obvious advan-
tage of these small-molecule compounds is their size. The 
blood–brain barrier is at least in part regulated by ATP-binding 
cassette (ABC) transporters, which contribute to multidrug 
resistance by actively extruding the drug compounds. Recent 
studies have shown that lapatinib is a substrate as well as an 
inhibitor of ABCB1, potentially explaining why brain concen-
trations of lapatinib tend to be lower.51 However, in contrast 
with lapatinib, neratinib has been shown to reverse ABCB1-
mediated chemoresistance52 and it is unaltered by the presence 
of the ABCG2 transporter.53 Moreover, neratinib could inhibit 
the function of this transporter at higher doses, leading to an 
increased level of ABCG2 substrate drugs within cells.53 At 
the 2014 American Society of Clinical Oncology annual meet-
ing, the preliminary data from a clinical trial investigating the 
efficacy of neratinib in HER2-positive breast cancer patients 
presenting with brain metastasis ( ClinicalTrials.gov identifier 
NCT01494662, see Table 2) suggested that neratinib could 
help to control disease in some HER2-positive breast cancer 
patients presenting with brain metastasis; however, the CNS 
overall response rate was only 7.5%.54
HER2-negative breast cancer
There is an interest in assessing whether neratinib could 
also be effective in breast tumors with lower HER2 expres-
sion, eg, immunohistochemistry (IHC) 2+ but fluorescence 
in situ hybridization (FISH)-negative patients. These will 
be those tumors that do not fulfill the current criteria for 
HER2-positive breast cancer. HER2 testing and its criteria 
have not always been consistent. Initially, the US Food and 
Drug Administration guidelines for HER2 testing recom-
mended that if $10% of the tumor cells show strong (3+) 
staining by IHC or if the HER2/chromosome 17 ratio at 
FISH is $2.0, the tumor is classified as HER2-positive.55 The 
threshold recommendations were updated by the American 
Society of Clinical Oncology/College of American Patholo-
gists to $30% of tumor cells with 3+ staining and a ratio of 
$2.2 for IHC and FISH, respectively, in 2007.56 However, the 
latest recommendation states thresholds similar to the initial 
guidelines.57 To be eligible for HER2 targeting treatments, 
breast cancer patients have to be classified as HER2-positive, 
depending on the local criteria used. However, IHC and FISH 
testing can be equivocal, and in two trials, patients initially 
classified as HER2-positive were found to be HER2-negative 
upon retesting. However, some of these negative patients still 
responded to treatment with trastuzumab.58,59
As the original HER2 positivity threshold was based on 
trastuzumab response, it is unknown whether the threshold 
should be different for TKIs such as lapatinib and neratinib, 
since there have been studies suggesting that breast can-
cer with a lower HER2 level may benefit from TKIs. For 
example, one study showed that patients with low HER2 by 
IHC may be more sensitive to lapatinib than to trastuzumab.60 
The I-SPY2 trial suggested that HER2-negative patients 
may benefit from the addition of neratinib to chemotherapy 
(see below).61
Triple-negative breast cancer
Triple negative breast cancer (TNBC) represents a group 
of heterogeneous breast cancers that lack expression of 
the estrogen receptor and progesterone receptor as well as 
HER2 overexpression or gene amplification. Patients with 
TNBC tend to have a poor prognosis and very aggressive 
breast cancer with a lack of targeted therapy options. EGFR 
is frequently overexpressed in TNBC, and thus there is an 
interest in targeting this subtype of cancer using EGFR 
inhibitors.62 It was reported that ADAM17 was expressed at 
significantly higher levels in TNBC than in non-TNBC, and 
an ADAM17 inhibitor could inhibit cell proliferation by a 
decrease of the release of the EGFR ligands and could also 
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enhance the response of TNBC cells to neratinib.63 However, 
despite the promising in vitro data, TNBC patients did not 
have a statistically significant improvement in pathological 
complete response (pCR) when treated with neratinib and 
chemotherapy in comparison with chemotherapy alone in the 
I-SPY 2 trial (see below).64 Moreover, a few trials involving 
cetuximab, an EGFR-targeting monoclonal antibody, have 
shown a poor response rate in patients with TNBC.65,66
This indicates that TNBC tumors are heterogeneous and 
may be driven by several different oncogenes other than 
EGFR. Therefore, targeting EGFR may only be suitable for 
a small subset of patients. Thus, the data so far show that the 
mechanisms of response and resistance to neratinib and other 
EGFR inhibitors in TNBCs are not well understood. There is 
therefore a need for further investigation of relevant predic-
tive biomarkers for use of EGFR inhibitors in TNBC.
Role of neratinib in treatment of tumors 
with EGFR, HER2, HER3, or HER4 
somatic mutations
EGFR
Previously, erlotinib and gefitinib have been found to be 
particularly effective against NSCLCs with EGFR mutations, 
including L858R EGFR mutation.67 However, secondary 
resistance is common due to an alternative T790M mutation, 
which causes increased affinity for ATP. However, this can be 
overcome by irreversible TKIs like afatinib, as they are not in 
a competitive equilibrium with ATP.68 Two trials have dem-
onstrated the clinical benefit of afatinib in patients with lung 
cancer who had progressed on erlotinib or gefitinib.69,70 The 
recent results from the LUX-Lung 3 trial showed superiority 
of afatinib with regard to response rate and progression-free 
survival over cisplatin and pemetrexed as first-line agents in 
treatment-naïve patients with advanced adenocarcinoma of 
the lung and EGFR mutation.71 Since then, afatinib has been 
approved for use in NSCLC with EGFR mutation. Since 
neratinib is a similar compound to afatinib as an irreversible 
TKI, there is an interest in assessing whether neratinib could 
be effective in solid tumors (including breast cancer) with 
EGFR mutations or amplification, and this is the basis for 
the Basket Study (NCT01953926, see below).
HER2
Similarly, neratinib could also be a treatment option for 
patients who carry a mutation in the HER2 protein. A recent 
publication evaluated data from eight breast cancer genome 
sequencing projects and identified a total of 13 somatic 
HER2 mutations, including seven activating mutations.72 
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This analysis showed that approximately 1.6% of all newly 
diagnosed breast cancers may harbor a HER2 mutation, and 
most of these patients do not have HER2 gene amplification 
or overexpression.72 This percentage might be higher for 
patients who have relapsed. Interestingly, all functionally 
characterized mutations were sensitive to neratinib, including 
those that rendered cells resistant to lapatinib.72 This provides 
the rationale for testing neratinib in patients with HER2 
mutations, including those with breast cancer.
HER3
Different studies have shown a 2%–4% prevalence of HER3 
mutations in breast cancer with evidence for occurrence in 
other cancer types as well.73 A majority of these somatic muta-
tions were identified in the extracellular region. Although not 
by themselves, in combination with HER2, these mutations 
promoted oncogenic signaling and enhanced colony forma-
tion and in vivo growth. However, several HER3 or HER2 
targeting agents, including trastuzumab and lapatinib, were 
effective in targeting these mutants,73 indicating that neratinib 
may also have an effect.
HER4
HER4 mutations have been found in 19% of patients with 
melanoma.74 A majority of these mutations are in the extracel-
lular domain of HER4 and affect, for example, ligand binding. 
HER4 mutations were found to increase kinase activity and 
transformation ability.74 Interestingly, melanoma cells with a 
HER4 mutation were sensitive to treatment with lapatinib.74 
As a result, lapatinib has been taken into clinical trials in 
melanoma, where patients with no more than two oncogenic 
somatic HER4 mutations will be offered lapatinib mono-
therapy (NCT01264081). Being an irreversible pan-HER 
inhibitor, neratinib could probably inhibit HER4 activation 
more effectively than lapatinib, although a head-to-head 
comparison trial has not been done. It will be interesting to 
assess whether neratinib is effective in tumors with HER4 
mutations, including melanoma and breast cancer.
Proposed resistance mechanisms
Despite the encouraging results, experience has shown that 
single treatment with targeting agents frequently triggers 
resistance mechanisms. Therefore, work is underway to 
investigate potential counteracting pathways that come into 
action during treatment with neratinib.
One in vitro study used a pool-based lentiviral genome-
wide functional RNA interference screen to discover genes 
which, if low or absent, would confer resistance to neratinib. 
Interestingly, the screen identified, among others, genes 
involved in oncogenesis, transcription factors, as well as 
genes known to interact with breast cancer-associated 
genes,75 highlighting the complexity of the cell machinery. 
One gene implicated was insulin-like growth factor binding 
protein 1, part of the insulin-like growth factor 1 pathway.75 
Another group identified miR-630 deficiency as a cause of 
neratinib resistance, at least partly due to its regulation of 
the insulin-like growth factor 1 receptor.76 Recently, expres-
sion of the neuropeptide neuromedin U was associated with 
a poor prognosis in HER2-overexpressing breast cancer 
and has been shown to correspond with resistance to HER-
targeting agents, including neratinib in vitro. It was suggested 
that neuromedin U acts through the chaperone heat shock 
protein 27 to aid HER2 stability.77 As with lapatinib,46 we 
observed a reactivation of HER3 and AKT phosphoryla-
tion after 24 hours of neratinib treatment in HER2-positive 
breast cancer cells, although we did not assess whether this 
was NRG1-dependent.26 In addition, our previous work 
showed that ADAM10 was upregulated in neratinib-treated 
breast cancer cells, albeit to a lesser extent compared with 
trastuzumab-treated cells;43 however, a thorough investigation 
was not carried out. Thus, it may be important to investigate 
whether HER ligand release mediated by ADAM10 and/or 
17, a resistance mechanism found in trastuzumab,42,43 also 
mediates acquired resistance to neratinib.
Biomarkers
Biomarker studies in vitro have identified several potential 
biomarkers, including HER2, AKT, ERK, and other potential 
markers for response to neratinib (see HER2-positive breast 
cancer section above). However, there are not much data avail-
able from clinical trials as yet. So far, the I-SPY 2 trial has 
shown that neratinib in addition to standard neoadjuvant che-
motherapy may be beneficial for patients with  HER2-positive 
breast cancer, and in particular for those who have hormone 
receptor-negative disease (pCR rate 56% vs 33% for patients 
treated with standard chemotherapy alone).64 Patients with 
hormone receptor-positive/HER2-positive disease also had 
a higher pCR rate with the addition of neratinib (30% vs 
17%).64 In the same study, patients were stratified according 
to their MammaPrint score (based on the median score of the 
I-SPY 1 trial). Patients with a higher score than the previous 
median MammaPrint score had a pCR of 47.5% if treated with 
a neratinib-containing regimen in comparison with 29.4% if 
treated with chemotherapy alone. Interestingly, 80.5% of these 
patients were negative for HER2.  Nevertheless, patients with 
TNBC did not seem to benefit;64 however, this subtype of 
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breast cancer is heterogeneous and other factors in addition 
to hormone receptor and HER2 status may be important. 
Further preclinical work as well as translational research using 
historical and prospective tumor samples from clinical trials 
will be needed to establish reliable biomarkers for neratinib 
response and resistance.
Clinical trials
Neratinib is currently being tested in various clinical trials 
for its safety and efficacy in various types of tumors, includ-
ing NSCLC, colorectal, bladder and breast cancers. The 
trials that have been registered with Clinicaltrials.gov as of 
December 2014 are listed in Table 3. However, in this sec-
tion, the main focus is on trials involving patients with breast 
cancer (Table 2).
Clinical trials in breast cancer
A Phase I dose-escalation study examined the safety and 
efficacy of neratinib at doses of 40–400 mg daily in patients 
with solid tumors. The absorption of neratinib was measured 
as median time to peak plasma concentration over 3–6.5 
hours. The steady-state peak plasma concentration and area 
under the concentration–time curve for neratinib increased in 
a dose-dependent manner from 40 to 320 mg, but plateaued 
at higher doses.78 Patients who received 40, 80, or 120 mg 
experienced no dose-limiting toxicities. This study deter-
mined the maximum tolerated dose at 320 mg, with 240 mg 
being the therapeutic dose.
In this dose-escalation study, 25 patients with breast can-
cer were evaluated for treatment efficacy; a partial response 
was observed in eight patients (32%), and stable disease 
for $24 weeks was found in one patient. The majority of 
responders had HER2-positive disease (IHC score 3+) and 
all had previously received trastuzumab, anthracyclines, 
and taxanes.78
Neratinib monotherapy in patients with HER2-positive 
advanced breast cancer was associated with a 16-week 
progression-free survival rate of 59% with a median 
progression-free survival of 22.3 weeks in patients who had 
received prior trastuzumab treatment; and a rate of 78% with 
a median progression-free survival of 39.6 weeks in patients 
who were trastuzumab-naïve. The objective response rates 
were 24% in patients with prior trastuzumab treatment and 
56% in the trastuzumab-naïve cohort.79 Similarly, a Phase I/II 
study exploring the combination of neratinib with vinore-
lbine in pretreated HER2-positive metastatic breast cancer 
showed an objective response of 8% in patients with prior 
lapatinib and 41% in patients who had no prior lapatinib, 
which was also mirrored in the respective progression-free 
survival rates.80
On the other hand, neratinib in combination with pacli-
taxel showed an overall response rate of 71% in patients who 
had not previously been treated with lapatinib and 77% in 
those with prior lapatinib.81 However, the number of patients 
in this trial was small. Overall, the combination was found 
to have increased toxicity but it achieved a better response 
rate relative to neratinib monotherapy. The overall response 
rate was 73% (95% confidence interval 62.9–81.2); seven 
patients (7%) had a complete response and another nine 
patients (9%) had stable disease for $24 weeks. The median 
progression-free survival was 57.0 weeks (95% confidence 
interval 47.7–81.6).81
Another study compared the combination of neratinib 
with weekly paclitaxel and trastuzumab in heavily pretreated 
patients with HER2-positive metastatic breast cancer and 
showed an overall clinical benefit (complete response + 
partial response + stable disease $24 weeks) in eleven 
patients (52%) with a median time to disease progression 
of 3.7 months.82 The addition of neratinib and/or trastu-
zumab to neoadjuvant paclitaxel followed by doxorubicin 
and cyclophosphamide chemotherapy is currently being 
tested in a Phase II randomized trial (ClinicalTrials.gov 
identifier NCT 01008150).82 Neratinib in combination with 
the mammalian target of rapamycin inhibitor temsirolimus 
was found to be tolerable and to be potentially beneficial 
in HER2-positive, trastuzumab-resistant breast cancer and 
HER2-mutant NSCLC in a Phase I study; however, numbers 
were small.83
Throughout the studies, the most common adverse event 
was diarrhea of any grade (up to 93%), especially during 
the first week of treatment; other adverse events included 
nausea, fatigue, vomiting, neutropenia, and anorexia.79,81 In 
the initial dose-escalation study, diarrhea (32%) was also 
the most common grade 3 or higher adverse event. In addi-
tion, it was the cause of dose reduction in 19 of 22 patients 
and was the adverse event that most frequently led to treat-
ment discontinuation (14%).26 This dose-escalation study 
suggested a potential relationship between neratinib dose/
exposure and diarrhea,78 but a follow-up study by Abbas 
et al revealed that there was no difference in the onset or 
severity of diarrhea in healthy subjects who were given 
neratinib either 240 mg once daily or 120 mg twice daily.84 
However, several studies have reported that diarrhea could 
be controlled with concurrent use of antidiarrheal agents.79,81 
Thus, primary prophylactic use of antidiarrheal medication 
is now mandatory for all patients taking neratinib in recent 
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clinical trials, which has helped to reduce the incidence of 
diarrhea.
A common side effect of anti-HER2 treatments, includ-
ing trastuzumab, is cardiac in nature, ie, a decrease in left 
ventricular ejection fraction. Neratinib was investigated in 
healthy subjects with regard to its effect on cardiac repolar-
ization and was shown not to prolong the QTc interval in 
comparison with controls.85 However, the possible long-term 
cardiac toxicity from addition of neratinib to trastuzumab 
and/or chemotherapy will not be known until the ongoing 
clinical trials yield mature safety data.
Ongoing trials
Since neratinib was often more potent than lapatinib in 
the preclinical setting, there is interest in comparing the 
clinical efficacy of these two TKIs. Neratinib monotherapy 
has previously been compared with the combination of 
lapatinib and capecitabine; however, this study could 
determine neither inferiority nor noninferiority of nera-
tinib.86 Overall survival was slightly better in the lapatinib 
+ capecitabine arm, but this difference was not statistically 
significant.86 In addition, neratinib monotherapy may not 
be directly comparable with a combination of lapatinib 
and chemotherapy since the anti-HER2 treatment response 
could be enhanced by addition of concurrent chemotherapy. 
A  subsequent study comparing neratinib + capecitabine 
with lapatinib + capecitabine in patients with HER2-
positive metastatic breast cancer who have received two or 
more prior HER2-directed regimens in the metastatic set-
ting (ClinicalTrials.gov identifier NCT01808573, NALA) 
is currently ongoing.
The ExteNET trial is comparing extended adjuvant 
neratinib vs placebo in HER2-positive patients with prior 
adjuvant trastuzumab. The primary endpoint is disease-free 
survival, which was increased by 33% in the neratinib arm 
(hazard ratio 0.67, P=0.0046) compared with the placebo 
arm. With regard to the secondary endpoint, ie, disease-free 
survival including for ductal carcinoma in situ, there was 
a 37% improvement in the neratinib arm compared with 
the placebo arm (hazard ratio 0.63, P=0.0009). Full results 
are expected soon. However, based on these results, Puma 
Biotechnology is planning to apply for approval of neratinib 
in the extended adjuvant setting in the first half of 2015.87 
In view of the effect of neratinib on HER receptor somatic 
mutations (see above), Puma Biotechnology has started an 
open-label Phase II study of neratinib in patients with solid 
tumors carrying somatic mutations of EGFR, HER2 or 
HER3, or EGFR gene amplification (BASKET study).88
Conclusion
Neratinib is a potent, irreversible, pan-HER inhibitor that has 
shown promising activity in preclinical as well as clinical 
studies with an acceptable safety profile in humans. However, 
further elucidation is needed to determine when and in which 
combination this compound should be used. Although most 
studies showed that neratinib offers the greatest benefit to 
patients with HER2-positive breast cancer, some data indicate 
that some HER2-negative patients may also benefit. Moreover, 
neratinib is now being tested in many solid tumors carrying 
EGFR, HER2, or HER3 mutations, or EGFR amplification. 
It will be interesting to see where neratinib will be positioned 
in relation to other available HER-targeting antibodies as well 
as TKIs. Ongoing studies will help to better define patients 
likely to benefit most from neratinib-containing treatments 
and the associated predictive biomarkers.
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